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Objectives The aim of this study was to evaluate vascular complications in a consecutive patient population undergoing trans-
femoral percutaneous aortic valve replacement (PAVR) applying current Valve Academic Research Consortium
definitions.
Background Vascular complications have been the major cause of mortality and morbidity associated with PAVR. Both open
surgical and fully percutaneous access site strategies have been advocated.
Methods All patients undergoing transfemoral PAVR during fiscal years 2009 and 2010 were prospectively evaluated at
baseline, after the procedure, and at 30 days.
Results PAVR was performed in 137 consecutive patients. All but 1 patient underwent planned arteriotomy closure using a
percutaneous pre-closure technique. Smaller sheaths, rigorous angiographic and computed tomographic screening
and patient selection, and percutaneous vascular repair techniques were increasingly used over this period. From
2009 to 2010, major vascular complications decreased from 8% to 1% (p  0.06), minor vascular complications
decreased from 24% to 8% (p  0.01), major bleeds fell from 14% to 1% (p  0.01), and unplanned surgery de-
creased from 28% to 2% (p  0.01). A minimal artery diameter smaller than the external sheath diameter, moderate
or severe calcification, and peripheral vascular disease were associated with higher vascular complication rates.
Conclusions Vascular complications occur more often if the minimal artery diameter is smaller than the external sheath di-
ameter, in the presence of moderate or severe calcification, and in patients with peripheral vascular disease.
With careful patient selection, advanced interventional techniques, and a fully percutaneous procedure, marked
reductions in vascular and bleeding complications can be achieved. (J Am Coll Cardiol 2012;59:113–8)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.069Vascular complications have emerged as the major cause of
mortality and morbidity when using the large catheters
required for percutaneous aortic valve replacement (PAVR)
(1–4). Studies have yielded a wide range of vascular com-
plication rates, influenced by clinical factors, but also by
nonuniform definitions of what constitutes a vascular com-
plication and by diagnostic rigor (1–11). For instance, the
large 22- to 24-F sheaths required for the SAPIEN valve
(Edwards Lifesciences Inc., Irvine, California) were associ-
From the *Department of Cardiology, St. Paul’s Hospital, University of British
Columbia, Vancouver, British Columbia, Canada; †Department of Radiology, St.
Paul’s Hospital, University of British Columbia, Vancouver, British Columbia,
Canada; and the ‡Department of Cardiovascular Surgery, St. Paul’s Hospital,
University of British Columbia, Vancouver, British Columbia, Canada. Drs. Togg-
weiler and Binder are supported by a grant from the Swiss National Foundation. Drs.
Leipsic, Wood, Cheung, Ye, and Webb are consultants to Edwards Lifesciences. All
other authors have reported that they have no relationships relevant to the contents of
this paper to disclose.Manuscript received April 14, 2011; revised manuscript received July 26, 2011,
accepted August 2, 2011.ated with vascular complication rates of 22.9% in the large
European SOURCE (SAPIEN Aortic Bioprosthesis Euro-
pean Outcome) registry (4) and 30.7% in the rigorously
monitored North American PARTNER 1B (Placement of
Aortic Transcatheter Valves) trial (1). The smaller 18-F
sheaths required for the third-generation CoreValve deliv-
ery system (Medtronic Inc., Minneapolis, Minnesota) have
been associated with lower reported vascular complication
rates, ranging from 1.9% to 13.3% (3,5,6,10,11). Vascular
complication rates with the similarly low-profile 18- to 19-F
SAPIEN XT NovaFlex delivery system (Edwards Life-
sciences Inc.) are not yet available.
See page 128
Recently, the Valve Academic Research Consortium
(VARC) proposed standardized definitions for clinical end-
points in transcatheter valve procedures in an effort to allow
comparison between clinical trials (Table 1) (12,13). The
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vascular complications in a consec-
utive patient population undergo-
ing PAVR using current tech-
niques applying current VARC
definitions.
Methods
Study population. All patients
undergoing transfemoral PAVR
at our center between April 2009 and March 2011 were
enrolled into a prospective registry. Femoral arterial access
was the default transcatheter approach, with apical or
axillary access used in the presence of small or diseased
iliofemoral arteries. All patients gave written informed
consent. Patients were assessed at baseline, after the proce-
dure, at hospital discharge, and at 30 days. Patients under-
going their procedure during the institutional fiscal year
2009 (April 2009 to March 2010) were compared with
those during the fiscal year 2010 (April 2010 to March
2011).
Vascular access evaluation. All patients underwent an-
giography of the descending aorta with fluoroscopic
imaging of both iliofemoral arteries to the level of the
femoral head. A calibrated pigtail (Royal Flush, Cook
Inc., Bloomington, Indiana) was used to facilitate esti-
mation of minimal arterial diameter. We used peripheral
angiography at the time of routine cardiac catheterization
as the initial evaluation of vascular access, and, if access
appeared borderline, multidetector computed tomo-
graphic angiography (MDCT) was used to further eval-
uate arterial diameter and the distribution and extent of
calcification.
Abbreviations
and Acronyms
MDCT  multidetector
computed tomographic
angiography
PAVR  percutaneous
aortic valve replacement
VARC  Valve Academic
Research Consortium
Vascular Complications According to ValveAcademic Research Consortium Definitions (12,13)Table 1 Vas ular Complications According to ValveAcademic Research Consortium Definitions (12,13)
Major vascular complications
Left ventricular perforation
Any thoracic aortic dissection
Access site or access-related vascular injury (dissection, stenosis, perforation,
rupture, arteriovenous fistula, pseudoaneurysm, hematoma, irreversible
nerve injury, or compartment syndrome) leading to either death, need for
significant blood transfusions (4 U), unplanned percutaneous or surgical
intervention, or irreversible end-organ damage (e.g., hypogastric artery
occlusion causing visceral ischemia or spinal artery injury causing
neurological impairment)
Distal embolization (noncerebral) from a vascular source requiring surgery or
resulting in amputation or irreversible end-organ damage
Minor vascular complications
Access site or access-related vascular injury (dissection, stenosis, perforation,
rupture, arteriovenous fistula or pseudoaneurysms requiring compression
or thrombin injection therapy, or hematomas requiring transfusion of 2
but 4 U) not requiring unplanned percutaneous or surgical intervention
and not resulting in irreversible end-organ damage
Distal embolization treated with embolectomy and/or thrombectomy and not
resulting in amputation or irreversible end-organ damage
Failure of percutaneous access site closure resulting in interventional (e.g.,
stent-graft) or surgical correction and not associated with death, need for
significant blood transfusions (4 U), or irreversible end-organ damageA subset of patients (n  82) were also screened with
MDCT performed on a 64-slice Discovery HD 750 High
Definition scanner (GE Healthcare, Milwaukee, Wiscon-
sin). Minimal luminal diameter measurements were per-
formed by measuring perpendicular to the vessel axis.
Tortuosity was determined on the basis of the most severe
angulation of the right iliofemoral system in anterior/
posterior or medial/lateral direction.
Fluoroscopic calcification was graded as none, mild (some
calcification), moderate (the course of the artery can be seen
without injection of contrast dye), or severe (heavily calcified
iliofemoral arteries). MDCT calcification was graded similarly.
Arterial access. The screening angiogram and MDCT
were reviewed, and the side with the larger, less tortuous,
less diseased iliofemoral artery was selected for insertion of
the large sheath. The proposed puncture site was routinely
assessed with fluoroscopy to assure its position relative to
the femoral head and prior angiogram. When necessary, a
catheter was advanced from the contralateral femoral artery,
or ultrasound was utilized to guide puncture. In a subset of
patients, 14- to 18-F expandable sheaths where used and
expanded to 18- to 19-F after insertion.
Anticoagulation. Patients were pre-medicated with aspirin
325 mg and clopidogrel 300 mg before the procedure. After
introduction of the large sheath, heparin was administered to
achieve an activated clotting time of 250 s. Protamine
reversal was used only in patients with ongoing bleeding.
Arterial closure. In all but 1 patient, pre-closure was per-
formed using either 2 ProGlide devices (sutures implanted at
10 and 2 o’clock) or 1 Prostar device (Abbott Vascular Inc,
Redwood City, California). After closure, contralateral ilio-
femoral angiography was performed unless the total amount of
Figure 1 Puncture and Closure of the Common Femoral Artery
(A) Puncture of the common femoral artery overlying the middle of the femoral
head. (B) Angiography using a contralateral catheter confirmed successful
percutaneous closure.contrast dye was felt to be too high in relation to the patient’s
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quantified offline using Quantitative Vascular Analysis (Philips
Xcelera, Philips, Amsterdam, the Netherlands).
Definition of endpoints. Vascular complications were de-
fined according to the VARC definitions as summarized in
Table 1 (12,13).
Statistical analysis. If not indicated otherwise, data are
presented as mean  SD for continuous and as number and
Figure 2 Percutaneous Management of Common Femoral Arter
Preclosure successfully achieved hemostasis. However, routine cross-over femora
a likely thrombus (A). This was dilated with a balloon using a cross-over technique
Baseline Characteristics in Patients Without and(n  137)Table 2 Bas line Characteris ics in Pa ients(n  137)
No
Female
Age (yrs)
Diabetes
Hypertension
Coronary artery disease
Prior acute myocardial infarction
Prior cerebrovascular accident
Prior open heart surgery
NYHA functional class III or IV
Chronic kidney failure
STS score
Peripheral vascular disease
Porcelain aorta
Abdominal or iliac aneurysm
Sheath size 19-F
Minimal artery diameter (mm)
Minimal artery diameter  sheath external diameter
Moderate or severe calcification on fluoroscopy
Length of hospital stay (days)Values are n (%) or mean  SD.
NYHA  New York Heart Association; STS  Society of Thoracic Surgeons.frequency for categorical variables. Continuous parametric
variables were compared using Student t test. Continuous
onparametric variables (Society of Thoracic Surgeons score,
ength of hospital stay) were compared using the Mann-
hitney U test for 2 test groups and the Kruskal-Wallis test
or 2 groups. Categorical variables were compared using the
hi-square test and Fisher exact test, where appropriate. A 2-sided
value of 0.05 was considered statistically significant.
clusion
graphy showed occlusion of the common femoral artery with
rrow) with residual mild stenosis (C, arrow). Recovery was uneventful.
Vascular Complicationsout and With Vas ular Complications
ular Complication
(n  113)
Vascular Complication
(n  24) p Value
40 (35) 12 (50) 0.18
83 8 83 7 0.89
36 (32) 8 (33) 0.89
89 (79) 17 (71) 0.43
87 (77) 22 (92) 0.11
23 (20) 6 (25) 0.61
12 (11) 2 (8) 0.74
32 (28) 9 (38) 0.37
106 (94) 21 (88) 0.28
42 (40) 12 (35) 0.60
7.4 3.7 7.6 3.5 0.72
12 (11) 7 (29) 0.02
4 (4) 3 (13) 0.07
8 (7) 2 (8) 0.83
16 (16) 4 (17) 0.93
7.8 1.1 7.7 1.4 0.74
48 (43) 15 (68) 0.03
36 (32) 8 (33) 0.89
6.1 3.9 11.8 10.1 0.01y Oc
l angio
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A total of 137 patients were analyzed, with the Edwards
SAPIEN XT valve implanted in 96 patients, SAPIEN in 25
patients, Medtronic CoreValve in 11 patients, and miscel-
laneous prototype valves (all using an 18-F sheath) in 5
patients.
Arterial closure. Pre-closure with either 2 ProGlide (n 
131) or 1 ProStar (n  5) was used routinely. One patient
underwent planned surgical cut-down at the surgeon’s
request. Cross-over angiography to assess the femoral access
site after percutaneous closure was performed in 89 patients
(65%), documenting a mean residual stenosis of 38  18%
Figure 3
Vascular Complications, Major Bleeding, and
Unplanned Surgery According to Arterial Minimal
Diameter and Sheath External Diameter as
Measured by Iliofemoral Angiography
The rate of vascular complications (major and minor combined) was higher
when minimal artery diameter was smaller than the external sheath diameter
(24% vs. 10%, p  0.03). Such patients also required more unplanned
surgery. art.  artery; min.  minimal.
Changes in Procedural Characteristics and OutcTable 3 Changes in Procedural Characterist
Variable
Angiographic screening
MDCT screening
Ultrasound guided puncture
Sheath size 19 F
Expandable sheath*
Angiographic minimal artery diameter  external sheath di
All vascular complications
Major vascular complications
Minor vascular complications
Attempted percutaneous treatment of complications
Successful percutaneous treatment of complications
Unplanned surgery
Major bleeding
Blood transfusion 1 U
Length of hospital stay (days)Values are n (%) or mean  SD. *Expandable sheaths measured 14- to 18-F
MDCT  multidetector computed tomographic angiography.with femoral occlusion in 3 patients, 1 of whom underwent
surgical and 2 percutaneous treatment (Fig. 2).
Vascular complications. Minor and major vascular com-
plications occurred in 24 patients (18%); all but 2 were
iliofemoral. Major complications occurred in 5 patients
(4%), dissection or perforation of the iliac artery in 4 (3%),
and guidewire perforation of the left ventricle in 1 (1%).
Minor vascular complications occurred in 19 patients (14%),
with femoral bleeding, stenosis, or occlusion in 16 patients
(12%), pseudoaneurysm in 2 (1%), and retroperitoneal
bleeding in 1 (1%). Unplanned vascular surgery was per-
formed in 16 patients (12%). No aortic rupture or dissection
was observed, despite documented porcelain aorta in 7 (5%).
Table 2 summarizes baseline characteristics of patients
without and with vascular complications. Vascular complica-
tions were more common in patients with peripheral vascular
disease and when the minimal artery diameter exceeded the
external sheath diameter (Fig. 3). There were no intra-
procedural deaths. Mortality at 30 days was 5.1%; deaths were
due to heart failure (n 2), sudden death (n 2), pneumonia
(n 2), and ischemic bowel (n 1). No patient with a minor
vascular complication died, whereas 1 of 5 patients with a
major complication died within 30 days. Hospital stay was
longer in patients with major vascular complications than in
those with minor or no complications (16 17 days, 11 8
days, and 6 4 days, respectively, p  0.01).
Changes over time. As shown in Table 3 and Figure 4,
procedural characteristics and outcome differed between 2009
and 2010. In 2010, the smaller 18- to 19-F sheaths were used
in all but 2 patients. MDCT for additional screening of the
iliofemoral arteries, ultrasound-guided puncture, and expand-
able sheaths were used more frequently.
Vascular complications fell from 32% in 2009 to 9% in
2010 (p  0.01). Major complications fell from 8% to 1%
(p  0.05), minor complications fell from 24% to 8% (p 
Over Timend Outcome Over Time
2009 (n  50) 2010 (n  87) p Value
50 (100) 87 (100) N/A
22 (44) 60 (69) 0.01
0 (0) 32 (37) 0.01
20 (40) 2 (2) 0.01
6 (12) 16 (18) 0.33
r 37 (77) 26 (30) 0.01
16 (32) 8 (9) 0.01
4 (8) 1 (1) 0.06
12 (24) 7 (8) 0.01
2/16 (13) 5/8 (63) 0.02
2/2 (100) 5/5 (100) N/A
14 (28) 2 (2) 0.01
7 (14) 1 (1) 0.01
11 (22) 6 (7) 0.01
7.7 7.6 6.8 4.7 0.66omeics a
ameteand are expanded after insertion to accommodate larger valves.
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unplanned surgery fell from 28% to 2% (p  0.01).
Iliofemoral arterial screening using MDCT. MDCT-
determined minimal artery diameter less than sheath exter-
nal diameter was a strong predictor for vascular complica-
tions (23% vs. 5%, p  0.01), as was the presence of
moderate or severely calcified iliofemoral arteries (29% vs.
9%, p  0.03) (Table 4). Complications associated with
moderate or severely calcified iliofemoral arteries included
femoral access site stenosis requiring balloon dilation, access
site bleeding requiring a covered stent in 1 patient and
surgical repair in 1 patient, and iliofemoral artery dissection/
perforation requiring treatment in 2 patients.
Discussion
Vascular complications decreased dramatically over the study
period. From 2009 to 2010, major vascular complications fell
from 8% to 1%, minor vascular complications fell from 24% to
8%, and unplanned vascular surgery fell from 28% to 2%. As
might be expected, the reduction in vascular complications was
associated with a reduction in major bleeding from 14% to 1%,
the need for blood transfusion from 22% to 7%, and hospital
length of stay from 7.7 to 6.8 days.
Percutaneous access closure was used in some cases in
2008 and in all but 1 case in 2009 and 2010. This period saw
Figure 4 Rates of Vascular Complications, Major Bleeding,
and Unplanned Surgery 2009 Versus 2010
Vascular complications, major bleeding, and unplanned surgery
decreased over the study period.
MDCT Measurements in Patients Without and WTable 4 MDCT Measurements in Patients
Variable
No V
Minimal artery diameter (mm)
Minimal artery diameter sheath external diameter
Moderate or severe calcification
Maximal tortuosity 45°Values are mean  SD or n (%).
MDCT  multidetector computed tomographic angiography.a gradual transition from 22- to 24-F sheaths to smaller 18-
to 19-F sheaths and then even smaller expandable sheaths.
Vascular screening and patient selection with angiography
and MDCT became more rigorous and routine. Experience
with percutaneous vascular closure techniques increased,
and these were increasingly reliable. When vascular injury
did occur or when hemostasis was unsuccessful, percutane-
ous repair techniques (balloon occlusion or dilation, stent-
ing) were more frequently used, increasing from 13% to 63%
over the study period. It was apparent that most complica-
tions could be managed percutaneously.
Comparison with previous studies. The most common
complications associated with PAVR are vascular, and most
bleeding complications are the result of vascular injury.
Vascular and bleeding complications have been shown to be
a major cause of morbidity and mortality (1). Reported
vascular complications rates vary widely from 1.9% to 30.7%
(1–11). Unfortunately, nonuniform definitions and variable
diagnostic rigor prevent direct comparisons between studies.
However, the combined effect of increased experience and
smaller sheath size has been previously demonstrated
(14,15). Our study further documents sheath diameter and
iliofemoral calcification as predictors of complications. The
risk for vascular complications is higher in patients with a
minimal iliofemoral artery diameter that is smaller than the
external sheath diameter (as determined by angiography or
MDCT), in the presence of moderate or severe calcification
(as determined by MDCT), and in patients with peripheral
vascular disease. Even so, most such patients underwent
PAVR without vascular complications, suggesting the im-
portance of balancing the potential for risk and benefit.
Conclusions
Vascular complications occur more often if the minimal
artery diameter is smaller than the sheath external diameter,
in the presence of moderate or severe calcification, and in
patients with peripheral vascular disease. Open surgical
access and closure of the femoral artery has been advocated
to reduce complication rates when using the large sheaths
required for PAVR. However, this study suggests that with
careful patient selection and advanced interventional tech-
niques, very low complication rates can be achieved with a
fully percutaneous procedure.
ascular Complications (n  82)t and With Vascular Complications (n  82)
r Complication
 71)
Vascular Complication
(n  11) p Value
 1.1 7.0 1.0 0.04
(42) 9 (82) 0.01
(17) 5 (46) 0.03
(24) 1 (9) 0.27ith Vithou
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